Bayer (BAYRY) is preparing a $10.5B settlement plan to address ongoing and future cancer claims tied to Roundup, Bloomberg’s Jef Feeley and Sonja Wind report. Bayer is expected to propose a $7.5B class-action settlement in Missouri state court to resolve existing and potential Roundup lawsuits over a 20-year period, along with an additional $3B to settle current U.S. cases alleging the weedkiller caused non-Hodgkin’s lymphoma, people familiar with the plan say.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Essential Pharma announces acquisition of Ventavis from Bayer
- Bayer’s Finerenone CKD Trial Completion: What Investors Should Watch Next
- Bayer’s Sepsis–DIC Study Wraps Up: What the New Data Effort Means for BAYRY Investors
- Bristol Myers price target raised to $68 from $64 at BofA
- Truist incrementally positive on Bristol Myers after Bayer asundexian data